EGFR and metastatic colorectal cancer: Advances in the treatment of metastatic colorectal cancer (mCRC) include the development of new antitumoral agents, including epidermal growth factor receptor-targeted monoclonal antibodies (EGFR-mAbs) and tyrosine kinase inhibitors, and the use of biomarkers.